JP2020512382A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512382A5 JP2020512382A5 JP2019553811A JP2019553811A JP2020512382A5 JP 2020512382 A5 JP2020512382 A5 JP 2020512382A5 JP 2019553811 A JP2019553811 A JP 2019553811A JP 2019553811 A JP2019553811 A JP 2019553811A JP 2020512382 A5 JP2020512382 A5 JP 2020512382A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antibody according
- region
- cell activation
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 11
- 230000006044 T cell activation Effects 0.000 claims description 10
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 8
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 8
- 230000013595 glycosylation Effects 0.000 claims description 8
- 238000006206 glycosylation reaction Methods 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 4
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 4
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 4
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 230000001588 bifunctional effect Effects 0.000 claims description 4
- 230000033581 fucosylation Effects 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 2
- 230000000139 costimulatory effect Effects 0.000 claims description 2
- 230000004041 dendritic cell maturation Effects 0.000 claims description 2
- 230000035800 maturation Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- 241000711549 Hepacivirus C Species 0.000 description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- 208000032382 Ischaemic stroke Diseases 0.000 description 4
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 201000002661 Spondylitis Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 208000002741 leukoplakia Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022195338A JP2023025215A (ja) | 2017-03-29 | 2022-12-07 | Ｐｄ－ｌ１抗体およびｔａ－ｍｕｃ１抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU100150 | 2017-03-29 | ||
| LULU100150 | 2017-03-29 | ||
| EP17171013 | 2017-05-15 | ||
| EP17171013.0 | 2017-05-15 | ||
| PCT/EP2018/057844 WO2018178122A1 (en) | 2017-03-29 | 2018-03-28 | Pd-l1 and ta-muc1 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022195338A Division JP2023025215A (ja) | 2017-03-29 | 2022-12-07 | Ｐｄ－ｌ１抗体およびｔａ－ｍｕｃ１抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020512382A JP2020512382A (ja) | 2020-04-23 |
| JP2020512382A5 true JP2020512382A5 (enExample) | 2021-05-06 |
Family
ID=61965929
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553811A Pending JP2020512382A (ja) | 2017-03-29 | 2018-03-28 | Ｐｄ−ｌ１抗体およびｔａ−ｍｕｃ１抗体 |
| JP2022195338A Pending JP2023025215A (ja) | 2017-03-29 | 2022-12-07 | Ｐｄ－ｌ１抗体およびｔａ－ｍｕｃ１抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022195338A Pending JP2023025215A (ja) | 2017-03-29 | 2022-12-07 | Ｐｄ－ｌ１抗体およびｔａ－ｍｕｃ１抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200148785A1 (enExample) |
| EP (1) | EP3601349A1 (enExample) |
| JP (2) | JP2020512382A (enExample) |
| CN (1) | CN111315776A (enExample) |
| AU (1) | AU2018241916A1 (enExample) |
| CA (1) | CA3057758A1 (enExample) |
| WO (1) | WO2018178122A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| CA3090407A1 (en) | 2018-03-01 | 2019-09-06 | Glycotope Gmbh | Fusion protein constructs comprising an anti-muc1 antibody and il-15 |
| HUE067382T2 (hu) | 2018-05-18 | 2024-10-28 | Daiichi Sankyo Co Ltd | Anti-MUC1-exatecan antitest-hatóanyag konjugátum |
| AU2020261961B2 (en) * | 2019-04-26 | 2022-07-07 | I-Mab Biopharma Co., Ltd. | Human PD-L1 antibodies |
| KR20220119694A (ko) * | 2019-12-23 | 2022-08-30 | 마크로제닉스, 인크. | 암 치료를 위한 요법 |
| IL272389A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Kits containing antibodies to PD-L1 and their uses in therapy |
| JP2023537022A (ja) * | 2020-08-07 | 2023-08-30 | バイオ－テラ ソリュ－ションズ，エルティーディー． | 抗ｐｄ－ｌ１抗体及びその応用 |
| TW202523698A (zh) | 2023-07-31 | 2025-06-16 | 法商賽諾菲公司 | 抗ｇｐｒｃ５ｄ抗體及組成物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2807767B1 (fr) * | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| ATE430580T1 (de) * | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| CA2542046A1 (en) * | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
| KR20150126730A (ko) * | 2006-09-10 | 2015-11-12 | 글리코토페 게엠베하 | 항체 발현을 위한 골수성 백혈병 기원의 인간 세포의 용도 |
| EP2281844A1 (en) * | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
| KR101981873B1 (ko) * | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| CA2875486A1 (en) * | 2012-07-18 | 2014-01-23 | Glycotope Gmbh | Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation |
| KR20150144804A (ko) * | 2013-04-22 | 2015-12-28 | 글리코토페 게엠베하 | 낮은 푸코실화를 갖는 항ｅｇｆｒ 항체를 이용한 항암 치료 |
| AR097584A1 (es) * | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| MY189089A (en) * | 2013-12-17 | 2022-01-25 | Genentech Inc | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
-
2018
- 2018-03-28 US US16/499,058 patent/US20200148785A1/en not_active Abandoned
- 2018-03-28 CA CA3057758A patent/CA3057758A1/en active Pending
- 2018-03-28 EP EP18717256.4A patent/EP3601349A1/en not_active Withdrawn
- 2018-03-28 WO PCT/EP2018/057844 patent/WO2018178122A1/en not_active Ceased
- 2018-03-28 JP JP2019553811A patent/JP2020512382A/ja active Pending
- 2018-03-28 CN CN201880021270.7A patent/CN111315776A/zh active Pending
- 2018-03-28 AU AU2018241916A patent/AU2018241916A1/en not_active Abandoned
-
2022
- 2022-12-07 JP JP2022195338A patent/JP2023025215A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020512382A5 (enExample) | ||
| JP2013063981A5 (enExample) | ||
| JP2017526350A5 (enExample) | ||
| JP2017522891A5 (enExample) | ||
| MX2011012047A (es) | Inmunoglobulinas humanas anti-cd52. | |
| RU2018146050A (ru) | Биспецифические связывающие белки, которые связывают иммуномодулирующий белок и опухолевый антиген | |
| JP2015528003A5 (enExample) | ||
| JP2018138047A5 (enExample) | ||
| RU2014114172A (ru) | Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом | |
| JP2018522564A5 (enExample) | ||
| JP2017114866A5 (enExample) | ||
| JP2015517309A5 (enExample) | ||
| JP2012143232A5 (enExample) | ||
| JP2012501670A5 (enExample) | ||
| JP2016511750A5 (enExample) | ||
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| HRP20130883T4 (hr) | Međuvrsno specifična cd3-epsilon-vežuća domena | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| JP2014111644A5 (enExample) | ||
| HRP20120759T1 (hr) | Bispecifična veziva specifična između vrsta | |
| EP4464333A3 (en) | Anti-death receptor antibodies and methods of use thereof | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| HRP20191983T1 (hr) | Konstrukti protutijela za cdh19 i cd3 | |
| RU2014144143A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток | |
| JP2012500020A5 (enExample) |